Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis
Authors:
- 19 November 2021
- journal article
- review article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 42 (1) , 1-16
Abstract
Background and Objective In recent trials, sodium-glucose cotransporter 2 (SGLT2) inhibitors proved effective as treatment for heart failure. However, the relative efficacy of sacubitril/valsartan against SGLT2 inhibitor in patients with heart failure remains unknown. Hence, we performed a network meta-analysis to compare the effects of sacubitril/valsartan against SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure. Methods Four electronic databases (PubMed, Embase, Cochrane, SCOPUS) were searched for randomised-controlled trials (RCTs) published from 1st January 2000 to 25th September 2021. Two additional systematic reviews were conducted for RCTs of enalapril and valsartan to establish a common comparator arm. Frequentist network meta-analysis models were utilised to summarise the studies. Results Twenty-five RCTs were included, comprising a combined cohort of 47,275 patients. Network meta-analysis demonstrated that compared to SGLT2 inhibitors, sacubitril/valsartan achieved a larger hazard rate reduction in the composite of heart failure hospitalisation and cardiovascular death (hazard ratio [HR]: 0.86; 95% CI 0.75–0.98), cardiovascular death (HR: 0.78; 95% CI 0.65–0.94), and a larger mean change in systolic blood pressure at 8 or more months (weighted mean difference [WMD]: − 7.08 mmHg; 95% CI − 8.28 to − 5.89). There were no significant differences in treatment effects across heart failure hospitalisation, all-cause mortality, diastolic blood pressure at 12 weeks, and systolic blood pressure at 2–4 months. In patients with heart failure with reduced ejection fraction, sacubitril/valsartan achieved a 20% hazard rate reduction for cardiovascular death compared to SGLT2 inhibitors. Conclusions In patients with heart failure, sacubitril/valsartan was demonstrated to be superior to SGLT2 inhibitors in the treatment effect for the composite of heart failure hospitalisation and cardiovascular death, cardiovascular death, and long-term blood pressure.Keywords
Funding Information
- This work was supported by the National University of Singapore Yong Loo Lin School of Medicine’s Junior Academic Faculty Scheme to CS.
This publication has 48 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Epidemiology and risk profile of heart failureNature Reviews Cardiology, 2010
- A Randomized Double-Blind Trial of Enalapril in Older Patients With Heart Failure and Preserved Ejection FractionCirculation: Heart Failure, 2010
- A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effects of Valsartan on Exercise Time in Patients with Symptomatic Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2009
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Imputing missing standard deviations in meta-analyses can provide accurate resultsJournal of Clinical Epidemiology, 2006
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Comparison of two simplified severity scores (SAPS and APACHE II) for patients with acute myocardial infarctionCritical Care Medicine, 1989
- Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)The American Journal of Cardiology, 1988
- Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failureJACC, 1985